Corrigendum

Diagnostic radiography and adult acute myeloid leukemia:
an interview and medical chart review study

JM Pogoda, PW Nichols, RK Ross, DO Stram, DC Thomas and S Preston-Martin

British Journal of Cancer (2012) 107, 1204. doi:10.1038/bjc.2012.426 www.bjcancer.com
© 2012 Cancer Research UKCorrection to: British Journal of Cancer (2012) 104, 1482–1486,
doi:10.1038/bjc.2011.114

The full, correct Table 4 is now presented, below:

After publication, it was noted that the dose category labels
contained in Table 4 of this paper were presented at magnitude 100
times higher than was correct.**Table 4** Risk analysis of total estimated bone marrow dose from diagnostic imaging procedures in the 2–10 years before diagnosis, adjusted for SES^a

FAB group	Total estimated dose (mGy) ^b	Data from medical records					Data from interview				
		# Ca	# Co	OR	(95% CI)	P trend ^c	# Ca	# Co	OR	(95% CI)	P trend ^c
All ^d	≤ 10.00	234	236	1.0		0.28	295	290	1.0		0.70
	10.01–20.00	22	30	0.7	(0.4, 1.3)		31	46	0.6	(0.4, 1.0)	
	> 20.00	23	13	1.6	(0.8, 3.2)		18	8	2.5	(1.0, 6.0)	
M1	≤ 10.00	49	48	1.0		0.76	58	56	1.0		0.95
	10.01–20.00	4	3	1.3	(0.3, 5.9)		6	11	0.6	(0.2, 1.7)	
	> 20.00	2	4	0.5	(0.1, 2.9)		3	0	—		
M2	≤ 10.00	65	66	1.0		0.54	89	84	1.0		0.46
	10.01–20.00	6	10	0.7	(0.2, 2.1)		7	10	0.6	(0.2, 1.8)	
	> 20.00	8	3	2.2	(0.6, 9.0)		3	5	0.6	(0.1, 2.6)	
M3	≤ 10.00	22	24	1.0		0.27	27	31	1.0		0.18
	10.01–20.00	2	3	0.6	(0.1, 3.8)		1	2	0.5	(0.0, 5.5)	
	> 20.00	3	0	—			5	0	—		
M4 ^e	≤ 10.00	39	48	1.0		0.10	57	64	1.0		0.054
	10.01–20.00	8	5	2.0	(0.5, 8.1)		12	8	1.4	(0.5, 4.0)	
	> 20.00	7	1	6.7	(0.8, 55.4)		4	1	4.7	(0.5, 43.1)	
M5 ^f	≤ 10.00	17	16	1.0		0.63	18	19	1.0		0.96
	10.01–20.00	0	2	0.0	(0.0, —)		1	2	0.6	(0.1, 7.7)	
	> 20.00	2	1	1.9	(0.1, 53.1)		2	0	—		

Abbreviations: Ca = cases; CI = confidence interval; Co = control; FAB = French-American-British; OR = odds ratio; SES = socioeconomic status. ^aExcludes pairs in which either the case or control had prior radiation therapy and/or chemotherapy for cancer. ^bDose is likely to be consistently underestimated (see text). ^cTotal dose as a continuous variable. ^dIncludes 51 case-control pairs with unknown FAB subtype. ^eExcludes cases with FAB subtype M4eo. ^fIncludes cases with FAB subtypes M5A and M5B.